You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of a novel highly effective influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. STTR Phase I: A platform for biological information integration and knowledge discovery

    SBC: Insilicom LLC            Topic: BT

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to help researchers to identify novel scientific hypotheses and make discoveries by harnessing the power of big data being generated in biological and biomedical fields. It is well known that big data have significant commercial potential, but also present some new challenges. For example, ...

    STTR Phase I 2014 National Science Foundation
  4. STTR Phase I: Ferrofluidic enclosures for enhanced control of thermal and magnetic fields in spin-stabilized atomic micro-devices

    SBC: COMMET LLC            Topic: EW

    The broader impact/commercial potential of this project is determined by new consumer products and new industries which would flourish on portable and reliable atomic clocks, gyroscopes, and magnetometers when they become available. Proposed compact thermal and magnetic enclosure reduces the most bulky part of such devices and provides an avenue for further miniaturization. A chip-scale atomic clo ...

    STTR Phase I 2014 National Science Foundation
  5. STTR Phase I: SYNTHETIC JET BASED ROBUST MAV FLIGHT CONTROLLER

    SBC: High Technology Materials, LLC            Topic: EI

    This Small Business Technology Transfer Research (STTR) Phase I project initiates development of a conceptually new ?seamless? micro air vehicle (MAV) design based on distributed array of synthetic-jet micro-actuators (SJMAs) operating in a closed-loop flight control system to achieve unprecedented aircraft maneuvering and gust tolerance capabilities. A radical minimalism in the robust flight cont ...

    STTR Phase I 2014 National Science Foundation
  6. Assessing muscle health in older adults with electrical impedance myography

    SBC: Myolex Inc            Topic: NIA

    DESCRIPTION (provided by applicant): Sarcopenia, or the deterioration of muscle health with advancing age, is a major public health concern in the developed world. Some of the most important factors underlying the development of sarcopenia are age- relatedchange in muscle composition, including the replacement of muscle fibers by fat and the loss of muscle force production. Declines in muscle comp ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This interaction of MTI-101 with the surface of MM cells causesprogrammed cell necrosis, whereas all approved MM drugs cause apoptosis and so the novel mechanism of MTI-101 or MTI-like compounds makes it esp ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: NINDS

    PROJECT SUMMARY Spinal cord injury (SCI) is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss, axonal destruction, and demyelination during the secondary injury cascade. There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value. We have previously shown that central nervous sy ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government